Skip to main
  1. Stocks
  2. Progyny
  3. Forecast
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is supported by a differentiated fertility and family-building platform that combines Smart Cycles, a curated specialist network, and high-touch care advocacy to drive superior clinical outcomes and measurable ROI for employers. The CalPERS selection, effective July 1, 2027, validates that model after a rigorous review, while strong retention above 99%, a win rate above 50% on competitive deals, and a $8 bln TAM point to durable share gains and substantial underpenetration. Financially, 1Q26 revenue and EBITDA beat consensus, guidance was raised to $1.365B-$1.405B and $232M-$244M, and the company’s strong cash flow plus share repurchases reinforce confidence in long-term value creation.

Bears say

Progyny is facing a fundamentally weaker outlook because elevated attrition, utilization pressure, and a potential economic downturn could reduce membership levels and discourage employers from adopting fertility benefit plans. Competitive threats from traditional insurers and emerging start-ups, along with slower expansion into adjacent services and slower-than-expected new solution revenue, could further pressure growth and make revenue assumptions too aggressive. Sentiment is also vulnerable to a volatile political backdrop, as uncertainty around reproductive rights and unfavorable socioeconomic conditions may weigh on demand and lower utilization.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Progyny (PGNY) Analyst Forecast & Price Prediction

Get the latest Progyny (PGNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Progyny (PGNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Progyny (PGNY) Analyst Forecast & Price Prediction

Get the latest Progyny (PGNY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Progyny (PGNY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PGNY stock data and trends